公开(公告)号：US20240425478A1

公开(公告)日：2024-12-26

申请号：US18698664

申请日：2022-10-04

Applicant: Genentech, Inc.

Inventor： Jessica Marie GRANDNER ,  Kevin M. JOHNSON ,  Steven MAGNUSON ,  Jeremy Mark MURRAY ,  Brendan T. PARR ,  Vishal A. VERMA ,  Yong WANG ,  Mingshuo ZENG ,  Melissa A. ASHLEY

IPC: C07D401/12 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.

公开(公告)号：US20230119740A1

公开(公告)日：2023-04-20

申请号：US17862963

申请日：2022-07-12

Applicant: GENENTECH, INC.

Inventor： Samantha Alyson GREEN ,  Jessica Marie GRANDNER ,  Steven Thomas STABEN ,  Neri AMARA ,  Vishva M. DIXIT ,  Elisia VILLEMURE

IPC: C07D498/04 ,  A61K9/20 ,  A61K9/48 ,  A61K9/08 ,  A61K47/02 ,  A61K47/10 ,  A61K9/12 ,  A61K47/12 ,  A61K47/06 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides a compound of formula (I): or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.

公开(公告)号：US20250109142A1

公开(公告)日：2025-04-03

申请号：US18657963

申请日：2024-05-08

Applicant: GENENTECH, INC.

Inventor： Samantha Alyson GREEN ,  Jessica Marie GRANDNER ,  Steven Thomas STABEN ,  Neri AMARA ,  Vishva M. DIXIT ,  Elisia VILLEMURE

IPC: C07D498/04 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides a compound of formula (I): or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.